Last reviewed · How we verify
Neostigmine-sugammadex
Neostigmine-sugammadex, marketed by Onze Lieve Vrouw Hospital, is a combination drug currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | Neostigmine-sugammadex |
|---|---|
| Sponsor | Onze Lieve Vrouw Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- NMBA Reversal and Postoperative Urinary Retention
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
- Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial (PHASE3)
- Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery (PHASE3)
- The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction (PHASE4)
- Low Pressure Pneumoperitoneum and Postoperative Ileus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neostigmine-sugammadex CI brief — competitive landscape report
- Neostigmine-sugammadex updates RSS · CI watch RSS
- Onze Lieve Vrouw Hospital portfolio CI